التفاصيل البيبلوغرافية
| العنوان: |
Retifanlimab and Other Immune Checkpoint Inhibitors for Squamous Cell Anal Carcinoma. |
| المؤلفون: |
Mencel, Justin1, Rao, Sheela1 sheela.rao@rmh.nhs.uk |
| المصدر: |
touchREVIEWS in Oncology & Haematology. 2023, Vol. 19 Issue 1, p41-45. 5p. |
| مصطلحات موضوعية: |
*IMMUNE checkpoint inhibitors, *SQUAMOUS cell carcinoma, *COMBINATION drug therapy, *IPILIMUMAB, *THERAPEUTICS, *HUMAN papillomavirus |
| مصطلحات جغرافية: |
UNITED Kingdom |
| مستخلص: |
Metastatic squamous cell anal carcinoma (SCAC) accounts for almost 500 deaths per year in the UK. The optimal first-line treatment for metastatic SCAC consists of combination chemotherapy, which provides only modest benefit with a short duration of response. Currently, there is no established second-line treatment for chemorefractory disease. Retifanlimab (a programmed cell death protein 1 inhibitor) has shown promise in patients with refractory, metastatic SCAC based on the POD1UM-202 study, and has potential in the first-line setting in combination with chemotherapy. This article will review the current treatment paradigms for SCAC, including the future use of immune checkpoint inhibitors, with a focus on retifanlimab in the treatment of SCAC. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
